Wegovy Approved for MASH Indication, Becoming China's First Approved GLP-1RA for the Disease
nashnova research
China's drug regulator approved semaglutide (Wegovy) for metabolic dysfunction-associated steatohepatitis (MASH), making it the country's first and only GLP-1 receptor agonist cleared for the disease — extending its label from weight management and cardiovascular health into liver disease.
What exactly was approved — and for whom?
Wegovy (semaglutide injection) gained a new indication: treating MASH with moderate-to-severe liver fibrosis (stage F2–F3) in non-cirrhotic adults.
MASH — metabolic dysfunction-associated steatohepatitis — is the tipping point where fatty liver crosses from reversible into irreversible liver damage. Miss this window, and the next stop is cirrhosis or liver cancer.
GLP-1 receptor agonists — a drug class that mimics gut hormones, originally used for diabetes and weight loss — had no China approval for MASH until now. This means → Wegovy is the first and currently only GLP-1RA to hold a Chinese MASH license.
What did the clinical data show?
The approval rests on Part 1 of the ESSENCE Phase III trial, enrolling 1,197 patients with biopsy-confirmed MASH.
Key result: roughly 63% of the semaglutide group achieved MASH resolution without fibrosis worsening, versus about 34% on placebo — nearly double.
On fibrosis improvement: about 37% of the treatment group saw fibrosis improve without MASH worsening, versus roughly 22% on placebo.
A post-hoc analysis found semaglutide improved liver injury across subgroups regardless of how much weight patients lost. In plain terms = the liver benefit does not just come from losing weight — the drug has an independent protective effect on the liver.
Why does this fill a clinical gap?
Jia Jidong of Beijing Friendship Hospital noted that clinicians have long lacked effective drugs for fatty liver; practice relied mainly on telling patients to change their lifestyle.
This means → before this approval, doctors facing MASH patients had virtually no Phase III–validated prescription option to reach for.
Ji Linong of Peking University People's Hospital said combining lifestyle intervention with approved medical therapy could deliver broader, more durable health benefits for overweight or obese patients.
About one-third of Chinese adults have fatty liver; among the overweight or obese, prevalence reaches 81.8% — an enormous patient base.
What does this mean for Novo Nordisk's portfolio?
Novo Nordisk Greater China president Cai Yan said the approval marks semaglutide's completion of a "heart–kidney–liver–metabolic" clinical evidence framework.
In plain terms = one molecule now holds Chinese clinical endorsements across weight management, cardiovascular risk, and MASH — opening the commercial runway for a multi-indication franchise.
Per Novo Nordisk's disclosure, semaglutide has been validated in 58 global clinical studies, with more than 58 million patient-years of cumulative real-world exposure.
What still stands between approval and volume?
Novo Nordisk itself acknowledged that whether the MASH indication achieves scale in China depends on higher clinical diagnosis rates and progress on national reimbursement inclusion.
This reflects a structural reality: MASH has long been under-diagnosed — many patients simply do not know their fatty liver has already progressed to fibrosis.
This means → regulatory approval is only step one. Whether the diagnostic pipeline and the payer pipeline keep pace will determine the indication's real market size.
市场有风险，内容仅供研究参考，不构成投资建议。